Valneva SE ADR (VALN)

This article lists various ETFs that invest in Valneva SE stocks, providing details such as market value, weight, issuer, management style, focus, expense ratio, AUM, price, change percentage, and 3-year NAV total return. The ETFs cover different investment strategies, including genomics, immunology, healthcare, small-cap, and broader European markets, offering diverse options for investors interested in Valneva SE.

Research analysts are updating their forecasts for Valneva's Q3 earnings, with HC Wainwright raising its EPS forecast to a loss of $0.18 per share. The company reported a Q2 loss of $0.40 per share, missing consensus estimates, and its revenue also fell short. Analyst sentiment for Valneva remains mixed, resulting in a consensus "Hold" rating and an average price target of $11.98.

Valneva SE (EPA:VLA) reported quarterly results that fell short of analyst expectations, with revenues missing predictions and a larger-than-forecast statutory loss per share. Despite the negative report and an expected increase in future losses, analysts have raised their average price target, suggesting they view the losses as temporary or not impacting long-term value. However, there's a wide spread in analyst estimates, indicating uncertainty about the company's future valuation.

Valneva SE reported quarterly results that fell short of analyst revenue predictions, with the company posting a larger-than-expected statutory loss per share. Despite the negative earnings, analysts have increased their average price target for Valneva by 19%, suggesting that the losses might be perceived as temporary or not impactful on the long-term value of the business. However, analysts still forecast higher losses for next year and expect the company's revenue growth to be slower than the broader industry.

Valneva SE reported total revenues exceeding €170 million for the full year 2025, with product sales near €160 million. While the company achieved a significant reduction in operating cash burn and refinanced its debt, it also faced a 3.3% decrease in product sales, an operating loss of €82.1 million, and increased R&D expenses. Valneva is focused on becoming a leading vaccine biotech company, anticipating pivotal Phase 3 results for its Lyme disease vaccine program with Pfizer.